Tenax Therapeutics Files Proxy Materials

TL;DR

Tenax Therapeutics filed proxy docs, shareholders vote soon.

AI Summary

Tenax Therapeutics, Inc. filed a Definitive Additional Materials proxy statement on May 24, 2024. This filing relates to the company's solicitation of proxies for its upcoming annual meeting. The company, formerly known as Oxygen Biotherapeutics, Inc., is based in Chapel Hill, NC.

Why It Matters

This filing is a routine but important step for publicly traded companies to communicate with shareholders regarding important corporate matters and upcoming votes.

Risk Assessment

Risk Level: low — This filing is a standard proxy statement, not indicating any immediate financial or operational risks.

Key Players & Entities

• TENAX THERAPEUTICS, INC. (company) — Registrant
• Oxygen Biotherapeutics, Inc. (company) — Former company name
• 20240524 (date) — Filing date

FAQ

Key Financial Figures

• $10,000 — on firm, at an approximate base cost of $10,000 (plus variable amounts for additional p

Filing Documents

• tenx_defa14a.htm (DEFA14A) — 12KB
• tenx_defa14aimg2.jpg (GRAPHIC) — 6KB
• 0001654954-24-006916.txt ( ) — 22KB

From the Filing

tenx_defa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under Rule 14a-12 TENAX THERAPEUTICS, INC. (Name of Registrant as Specified In Its Charter) Not Applicable (Name of Person(s) Filing Proxy Statement if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. TENAX THERAPEUTICS, INC. 101 Glen Lennox Drive, Suite 300 Chapel Hill, North Carolina 27517 (919) 855-2100 Proxy Statement Supplement Dated May 24, 2024 Annual Meeting of Stockholders To Be Held on June 7, 2024 The following information supplements and should be read in conjunction with the Proxy Statement dated April 26, 2024 of Tenax Therapeutics, Inc. (the "Company"), which was filed with the SEC on or about April 26, 2024 (the "Proxy Statement"). Terms defined in the Proxy Statement have the same meaning herein, unless the context otherwise requires. Except as specifically supplemented by the information contained herein, all information set forth in the Proxy Statement remains unchanged. From and after the date of this supplement, all references to the "Proxy Statement" are to the Proxy Statement as supplemented hereby. Supplemental Disclosure The Company is providing this supplement to reflect the following updates to the disclosure in the Proxy Statement: Proxy Solicitor The Company has retained Morrow Sodali LLC ("Morrow Sodali"), a professional proxy solicitation firm, at an approximate base cost of $10,000 (plus variable amounts for additional proxy solicitation services and related expenses), to solicit proxies on behalf of the Company in connection with the Annual Meeting. Morrow Sodali may solicit the return of proxies, either by mail, telephone, email or through personal contact. The cost of solicitation will be borne by the Company, including the fees and certain expenses of Morrow Sodali. If you have any questions regarding the proposals set forth in the Proxy Statement or require assistance with voting your shares in connection with the Annual Meeting, please contact Morrow Sodali by email at Tenx.info@investor.morrowsodali.com. You may also reach Morrow Sodali by telephone at 800-607-0088 (for stockholders) or 203-658-9400 (for banks and brokers).

View Full Filing

View this DEFA14A filing on SEC EDGAR